Meliglix (Sitagliptin)

Sitagliptin inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), preventing the breakdown of incretin hormones GLP‑1 and GIP. This prolongs their activity, leading to increased insulin secretion and reduced glucagon release in a glucose‑dependent manner, which together lower blood sugar levels.

The dose of Meliglix is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. The prescriber determines the appropriate strength, frequency, and any necessary adjustments.

Safety of sitagliptin in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Meliglix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, and will request trade or institutional credentials before providing pricing, availability, shipping details and any required import documentation.

Compared with sulfonylureas, sitagliptin has a lower risk of causing hypoglycemia because its effect is glucose‑dependent. Unlike insulin, it is an oral agent and does not require injection. It is often positioned as an add‑on therapy when metformin alone does not achieve target glycemic control.

Meliglix tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging, protect from moisture and direct sunlight, and keep out of reach of children. Do not store in the refrigerator or freezer.

Meliglix is taken orally, usually once daily with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

The most serious risks include pancreatitis, which may present as severe abdominal pain, and severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome. Joint pain (arthralgia) and rare skin disorders like bullous pemphigoid have also been reported and warrant prompt medical evaluation.

Meliglix should be avoided in patients with a known hypersensitivity to sitagliptin or any component of the formulation. It is also contraindicated in individuals with a history of pancreatitis and should be used with caution in patients with severe renal impairment unless dose adjustments are made.